Amai Proteins

Company Overview

Snapshot

Founded in December 2016 by Ilan Samish, Amai Proteins operates with 51–200 employees. The company has raised $22.82 million across 12 funding rounds from 11 investors. In February 2026, Amai Proteins announced that its flagship sweet protein, Sweelin®, received Generally Recognized As Safe (GRAS) approval from the U.S. FDA, paving the way for accelerated commercialization in the U.S. market.

Business overview

Amai Proteins specializes in developing designer proteins as sugar substitutes for the food and beverage industry. Its core product, Sweelin®, is a hyper-sweet protein derived from the serendipity berry, engineered to reduce added sugar in products by 40-70% without compromising taste, health, cost, or sustainability. The company utilizes its proprietary Pro-Cube platform, which integrates AI-driven computational protein design (Pro-Design AI-CPD), scalable microbial precision fermentation (Pro-Planet Microbial Precision Fermentation), and food technology assessment (Pro-Taste Food Technology) to produce stable, highly potent protein powders. Amai Proteins serves the global food and beverage market, operating within the Agriculture & Food Technologies sector, with a focus on novel food and ingredients.

Strategic signal

Amai Proteins is poised for significant market expansion following the U.S. FDA's GRAS approval for its Sweelin® protein in February 2026, which clears a major regulatory hurdle for commercialization in the U.S. This approval, coupled with earlier regulatory wins in other regions, signals strong validation of the company's technology and its potential to disrupt the global sugar substitute market. For investors, this indicates a de-risked pathway to broader adoption and revenue growth in a health-conscious consumer landscape.

Company Intelligence Q&A

What is Amai Proteins' flagship product?

Amai Proteins' flagship product is Sweelin®, a calorie-free sweet protein designed to reduce sugar content in food and beverages.

What significant regulatory approval did Amai Proteins receive in February 2026?

In February 2026, Amai Proteins announced that its Sweelin® protein received Generally Recognized As Safe (GRAS) approval from the U.S. FDA, facilitating its commercialization in the U.S. market.

What was a key regulatory milestone for Sweelin® in May 2026?

In May 2026, Amai Proteins announced that Sweelin® received approval from the Singapore Food Agency as a food additive, expanding the company's regulatory footprint into Asia.

What was the outcome of Amai Proteins' human clinical trial in December 2024?

In December 2024, Amai Proteins successfully completed the world's first human clinical trial on the effects of sweet proteins with Sweelin®, designed to meet consumer and industry needs.

When did Amai Proteins secure multiple regulatory approvals for Sweelin®?

In October 2024, Amai Proteins secured multiple regulatory approvals for its calorie-free sweet protein, Sweelin®.